Erbulozole
Erbulozole' (developmental code name R55104) is a pharmacological compound recognized as a congener of the microtubule inhibitor tubulozole. Positioned within the realm of cancer research, Erbulozole is currently being explored in phase I clinical trials for its potential as a chemotherapeutic agent. Its mechanism, akin to that of tubulozole, involves the inhibition of microtubule dynamics, a critical process in cell division (mitosis), making it a promising candidate for the treatment of various cancers by preventing the proliferation of cancer cells.
Pronunciation
Er-bu-lo-zole
Mechanism of Action
Erbulozole exerts its anticancer effects by targeting and inhibiting microtubules, which are essential components of the cell's cytoskeleton. Microtubules play a pivotal role in cell division, and their inhibition disrupts this process, effectively halting the growth and spread of cancer cells. This mechanism of action places Erbulozole in the category of microtubule inhibitors, a class of compounds that are of significant interest in oncology for their ability to target rapidly dividing cells.
Clinical Development
As of its current status, Erbulozole is undergoing phase I clinical trials. This initial phase of clinical testing is designed to evaluate the safety, tolerability, and optimal dosing of Erbulozole in humans, as well as to provide preliminary insights into its efficacy against cancer. The transition of Erbulozole into clinical trials underscores the continuous effort in the field of oncology to discover and develop novel therapeutic options for cancer treatment.
Related Terms
See Also
External links
- Medical encyclopedia article on Erbulozole
- Wikipedia's article - Erbulozole
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski